DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Stock analysts at Northcoast Research dropped their Q3 2018 earnings per share estimates for DENTSPLY SIRONA in a research note issued on Wednesday. Northcoast Research analyst E. Snyder now expects that the medical instruments supplier will post earnings of $0.77 per share for the quarter, down from their prior estimate of $0.79.

Several other research analysts have also recently issued reports on the company. HC Wainwright cut DENTSPLY SIRONA from a “buy” rating to a “neutral” rating and set a $68.00 price target on the stock. in a report on Thursday. Stephens began coverage on DENTSPLY SIRONA in a report on Tuesday. They issued an “overweight” rating and a $75.00 price target on the stock. TheStreet raised DENTSPLY SIRONA from a “c” rating to a “b-” rating in a report on Friday, November 3rd. Stifel Nicolaus boosted their target price on shares of DENTSPLY SIRONA from $66.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, November 6th. Finally, Barrington Research raised shares of DENTSPLY SIRONA from a “market perform” rating to an “outperform” rating and set a $73.00 target price on the stock in a research note on Monday, November 6th. Three research analysts have rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. DENTSPLY SIRONA has an average rating of “Hold” and an average target price of $67.73.

DENTSPLY SIRONA (XRAY) traded down $0.93 during midday trading on Friday, hitting $66.08. The company’s stock had a trading volume of 1,922,536 shares, compared to its average volume of 1,652,473. The company has a market capitalization of $15,390.00, a PE ratio of 27.32, a P/E/G ratio of 2.71 and a beta of 1.27. DENTSPLY SIRONA has a 52 week low of $52.53 and a 52 week high of $68.98. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.32 and a quick ratio of 1.59.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.66 by $0.04. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $978.99 million. DENTSPLY SIRONA had a return on equity of 4.93% and a net margin of 8.97%. The firm’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.66 earnings per share.

In related news, insider Mark Thierer purchased 77,000 shares of the stock in a transaction dated Monday, November 13th. The shares were acquired at an average cost of $66.04 per share, for a total transaction of $5,085,080.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Francis J. Lunger sold 8,900 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $65.90, for a total transaction of $586,510.00. The disclosure for this sale can be found here. 1.99% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of XRAY. Bessemer Group Inc. grew its holdings in shares of DENTSPLY SIRONA by 4,638.6% during the 3rd quarter. Bessemer Group Inc. now owns 1,903,596 shares of the medical instruments supplier’s stock valued at $113,855,000 after acquiring an additional 1,863,424 shares in the last quarter. Alyeska Investment Group L.P. grew its holdings in shares of DENTSPLY SIRONA by 223.7% during the 3rd quarter. Alyeska Investment Group L.P. now owns 2,271,534 shares of the medical instruments supplier’s stock valued at $135,860,000 after acquiring an additional 1,569,746 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of DENTSPLY SIRONA by 22.3% during the 2nd quarter. Principal Financial Group Inc. now owns 6,474,432 shares of the medical instruments supplier’s stock valued at $419,802,000 after acquiring an additional 1,181,547 shares in the last quarter. Jackson Square Partners LLC grew its holdings in shares of DENTSPLY SIRONA by 15.6% during the 3rd quarter. Jackson Square Partners LLC now owns 6,334,906 shares of the medical instruments supplier’s stock valued at $378,890,000 after acquiring an additional 855,199 shares in the last quarter. Finally, Parnassus Investments CA grew its holdings in shares of DENTSPLY SIRONA by 62.7% during the 3rd quarter. Parnassus Investments CA now owns 2,115,000 shares of the medical instruments supplier’s stock valued at $126,498,000 after acquiring an additional 815,000 shares in the last quarter. Institutional investors and hedge funds own 96.59% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “DENTSPLY SIRONA Inc. (XRAY) to Post Q3 2018 Earnings of $0.77 Per Share, Northcoast Research Forecasts” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/12/01/dentsply-sirona-inc-xray-to-post-q3-2018-earnings-of-0-77-per-share-northcoast-research-forecasts.html.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Earnings History and Estimates for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.